These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7610150)

  • 1. Lesion of descending 5-HT pathways increases zimeldine-induced waking in rats.
    Bjørkum AA; Neckelmann D; Bjorvatn B; Ursin R
    Physiol Behav; 1995 May; 57(5):959-66. PubMed ID: 7610150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased waking as well as increased synchronization following administration of selective 5-HT uptake inhibitors to rats.
    Ursin R; Bjorvatn B; Sommerfelt L; Underland G
    Behav Brain Res; 1989 Aug; 34(1-2):117-30. PubMed ID: 2527519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats.
    Bjorvatn B; Ursin R
    Behav Brain Res; 1990 Nov; 40(3):239-46. PubMed ID: 2149499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep/waking and EEG power spectrum effects of a nonselective serotonin (5-HT) antagonist and a selective 5-HT reuptake inhibitor given alone and in combination.
    Bjorvatn B; Bjørkum AA; Neckelmann D; Ursin R
    Sleep; 1995 Jul; 18(6):451-62. PubMed ID: 7481417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine on EEG sleep and waking stages in the rat.
    Kleinlogel H; Burki HR
    Neuropsychobiology; 1987; 17(4):206-12. PubMed ID: 2964564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral, sleep-waking and EEG power spectral effects following the two specific 5-HT uptake inhibitors zimeldine and alaproclate in cats.
    Sommerfelt L; Ursin R
    Behav Brain Res; 1991 Nov; 45(2):105-15. PubMed ID: 1838688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 5-HT1A antagonist (-)-alprenolol fails to modify sleep or zimeldine-induced sleep-waking effects in rats.
    Bjorvatn B; Neckelmann D; Ursin R
    Pharmacol Biochem Behav; 1992 May; 42(1):49-56. PubMed ID: 1388278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep-wake and eeg effects following adenosine a1 agonism and antagonism: similarities and interactions with sleep-wake and eeg effects following a serotonin reuptake inhibitor in rats.
    Ursin R; Bjorvatn B
    Sleep Res Online; 1998; 1(3):119-27. PubMed ID: 11382868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT2 antagonist ritanserin decreases sleep in cats.
    Sommerfelt L; Ursin R
    Sleep; 1993 Jan; 16(1):15-22. PubMed ID: 8456229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of zimeldine and alaproclate combined with a small dose of 5-HTP on waking and sleep stages in cats.
    Sommerfelt L; Ursin R
    Behav Brain Res; 1987 Apr; 24(1):1-10. PubMed ID: 2953350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diurnal differences in L-tryptophan sleep and temperature effects in the rat.
    Olsen OE; Neckelmann D; Ursin R
    Behav Brain Res; 1994 Dec; 65(2):195-203. PubMed ID: 7718152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effect on REM sleep but differential effect on slow wave sleep of the two 5-HT uptake inhibitors zimeldine and alaproclate in cats and rats.
    Sommerfelt L; Hauge ER; Ursin R
    J Neural Transm; 1987; 68(1-2):127-44. PubMed ID: 2949058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
    Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
    J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the selective alpha 1-adrenoceptor blocker prazosin on EEG sleep and waking stages in the rat.
    Kleinlogel H
    Neuropsychobiology; 1989; 21(2):100-3. PubMed ID: 2559357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of systemic atropine sulfate administration on the frequency content of the cat sensorimotor EEG during sleep and waking.
    Szymusiak R; McGinty D; Shouse MN; Shepard D; Sterman MB
    Behav Neurosci; 1990 Feb; 104(1):217-25. PubMed ID: 2317279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the vigilance stages in the rat by fast Fourier transformation.
    Kleinlogel H
    Neuropsychobiology; 1990-1991; 23(4):197-204. PubMed ID: 2130289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic zimeldine administration to cats: sustained increase of serotonergic effect as measured with sleep parameters.
    Sommerfelt L
    Pharmacol Toxicol; 1990 Feb; 66(2):128-32. PubMed ID: 2138291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Purkinje cell response to glutamate during the sleep-waking cycle.
    Andre P; Arrighi P
    Neuroscience; 2001; 105(3):731-46. PubMed ID: 11516837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram.
    Neckelmann D; Bjørkum AA; Bjorvatn B; Ursin R
    Behav Brain Res; 1996 Feb; 75(1-2):159-68. PubMed ID: 8800653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide-S evoked arousal with electroencephalogram slow-wave compensatory drive in rats.
    Ahnaou A; Drinkenburg WH
    Neuropsychobiology; 2012 Jun; 65(4):195-205. PubMed ID: 22538299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.